- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT02491892
A Study of Pertuzumab in Participants With Metastatic Breast Cancer
24 sierpnia 2015 zaktualizowane przez: Hoffmann-La Roche
Open-Label, Phase II, Multicenter, Randomized Study of Efficacy and Safety for Two Different Doses of a Recombinant Humanized Antibody to HER2 (rhuMAb 2C4) Administered Every 3 Weeks to Patients With Metastatic Breast Cancer With Low Expression of HER2
This study will evaluate the efficacy and safety of pertuzumab (rhuMAb 2C4) in participants with metastatic breast cancer which has progressed during or after standard chemotherapy and which is not amenable to curative therapy.
Those who are maintaining a response to therapy or who have stable disease at the end of the formal study period will continue treatment until disease progression or unacceptable toxicity.
Approximately 120 participants will be enrolled.
Przegląd badań
Typ studiów
Interwencyjne
Zapisy (Rzeczywisty)
79
Faza
- Faza 2
Kontakty i lokalizacje
Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.
Lokalizacje studiów
-
-
-
Camperdown, Australia, 2050
-
Fitzroy, Australia, 3065
-
Geelong, Australia, 3220
-
-
-
-
-
Namur, Belgia, 5000
-
-
-
-
-
Helsinki, Finlandia, 00029
-
Tampere, Finlandia, 33520
-
-
-
-
-
Barcelona, Hiszpania, 08035
-
Barcelona, Hiszpania, 08907
-
Valencia, Hiszpania, 46009
-
-
-
-
-
Amsterdam, Holandia, 1081 HV
-
-
-
-
-
Hamburg, Niemcy, 20246
-
Herne, Niemcy, 44625
-
München, Niemcy, 81675
-
-
-
-
-
Milano, Włochy, 20133
-
Parma, Włochy, 43100
-
-
-
-
-
Edinburgh, Zjednoczone Królestwo, EH4 2XU
-
London, Zjednoczone Królestwo, SE1 9RT
-
Manchester, Zjednoczone Królestwo, M20 4BX
-
-
Kryteria uczestnictwa
Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.
Kryteria kwalifikacji
Wiek uprawniający do nauki
18 lat i starsze (Dorosły, Starszy dorosły)
Akceptuje zdrowych ochotników
Nie
Płeć kwalifikująca się do nauki
Kobieta
Opis
Inclusion Criteria:
- Females at least 18 years of age
- Histologically-confirmed metastatic breast cancer with low HER2 expression and at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST)
- Karnofsky performance status at least 80%
- Disease progression on/after up to 2 different chemotherapy regimens, including an anthracycline-containing therapy
- Left ventricular ejection fraction (LVEF) at least 50%
- Adequate liver function
Exclusion Criteria:
- Pleural effusions, ascites, or bone lesions as the only manifestation(s) of cancer
- Pulmonary or central nervous system (CNS) metastases
- Chemotherapy, radiotherapy, or immunotherapy within 4 weeks; or hormone therapy within 2 weeks of Day 1
- Previous treatment with any drug that targets the HER2 receptor family
- Previous treatment with corticosteroids as cancer therapy
- History of significant cardiac disease
- Major surgery or trauma within 4 weeks of Day 1
- Pregnant or lactating women
Plan studiów
Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
---|---|
Eksperymentalny: Pertuzumab 1050 mg
Participants will not receive a loading dose, but will receive pertuzumab 1050 milligrams (mg) via intravenous (IV) infusion every 3 weeks until unacceptable toxicity or disease progression.
|
Participants will receive one of two IV treatment regimens with pertuzumab: either 420 mg every 3 weeks, with an initial 840-mg loading dose, or 1050 mg every 3 weeks with no loading dose administered.
Inne nazwy:
|
Eksperymentalny: Pertuzumab 420 mg
Participants will receive a loading dose of 840 mg via IV infusion at the first infusion of pertuzumab, followed by a maintenance dose of 420 mg every 3 weeks until unacceptable toxicity or disease progression.
|
Participants will receive one of two IV treatment regimens with pertuzumab: either 420 mg every 3 weeks, with an initial 840-mg loading dose, or 1050 mg every 3 weeks with no loading dose administered.
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Percentage of Participants Achieving a Best Overall Response of Confirmed Complete Response (CR) or Partial Response (PR)
Ramy czasowe: Up to approximately 1 year (at Baseline; every 6 weeks for the first 8 cycles, then every 12 weeks until progression or death; and up to 4 weeks after initial response)
|
Objective tumor response was assessed using Response Evaluation Criteria in Solid Tumors (RECIST).
Confirmed CR was defined as the disappearance of all target lesions, and confirmed PR was defined as at least at 30 percent (%) decrease in the sum of the longest diameters of target lesions.
Response was to be confirmed at follow-up assessment completed within 4 weeks of the first documented response.
The percentage of participants achieving a best overall response of CR or PR was calculated as [number of participants meeting the above criteria divided by the number analyzed] multiplied by 100.
|
Up to approximately 1 year (at Baseline; every 6 weeks for the first 8 cycles, then every 12 weeks until progression or death; and up to 4 weeks after initial response)
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Time to Response Among Participants Achieving a Best Overall Response of Confirmed CR or PR
Ramy czasowe: Up to approximately 1 year (at Baseline; every 6 weeks for the first 8 cycles, then every 12 weeks until progression or death; and up to 4 weeks after initial response)
|
Objective tumor response was assessed using RECIST.
Confirmed CR was defined as the disappearance of all target lesions, and confirmed PR was defined as at least at 30% decrease in the sum of the longest diameters of target lesions.
Response was to be confirmed at follow-up assessment completed within 4 weeks of the first documented response.
Time to response was defined as the time from treatment start to first documented response (ie, CR or PR).
Participants with stable disease (SD) were censored from the last tumor assessment, and those with progressive disease (PD) or death were assigned an artificial censoring time of 1000 days.
Time to response was estimated using Kaplan-Meier and expressed in weeks.
|
Up to approximately 1 year (at Baseline; every 6 weeks for the first 8 cycles, then every 12 weeks until progression or death; and up to 4 weeks after initial response)
|
Duration of Response Among Participants Achieving a Best Overall Response of Confirmed CR or PR
Ramy czasowe: Up to approximately 1 year (at Baseline; every 6 weeks for the first 8 cycles, then every 12 weeks until progression or death; and up to 4 weeks after initial response)
|
Objective tumor response was assessed using RECIST.
Confirmed CR was defined as the disappearance of all target lesions, and confirmed PR was defined as at least at 30% decrease in the sum of the longest diameters of target lesions.
Response was to be confirmed at follow-up assessment completed within 4 weeks of the first documented response.
Duration of response was defined as the time from first documented response (ie, CR or PR) to PD or death.
Participants who did not experience PD or death were censored from the last tumor assessment.
Duration of response was estimated using Kaplan-Meier and expressed in weeks.
|
Up to approximately 1 year (at Baseline; every 6 weeks for the first 8 cycles, then every 12 weeks until progression or death; and up to 4 weeks after initial response)
|
Percentage of Participants Achieving a Best Overall Response of Confirmed CR
Ramy czasowe: Up to approximately 1 year (at Baseline; every 6 weeks for the first 8 cycles, then every 12 weeks until progression or death; and up to 4 weeks after initial response)
|
Objective tumor response was assessed using RECIST.
Confirmed CR was defined as the disappearance of all target lesions.
Response was to be confirmed at follow-up assessment completed within 4 weeks of the first documented response.
The percentage of participants achieving a best overall response of CR was calculated as [number of participants meeting the above criteria divided by the number analyzed] multiplied by 100.
|
Up to approximately 1 year (at Baseline; every 6 weeks for the first 8 cycles, then every 12 weeks until progression or death; and up to 4 weeks after initial response)
|
Duration of Response Among Participants Achieving a Best Overall Response of Confirmed CR
Ramy czasowe: Up to approximately 1 year (at Baseline; every 6 weeks for the first 8 cycles, then every 12 weeks until progression or death; and up to 4 weeks after initial response)
|
Objective tumor response was assessed using RECIST.
Confirmed CR was defined as the disappearance of all target lesions.
Response was to be confirmed at follow-up assessment completed within 4 weeks of the first documented response.
Duration of response was defined as the time from first documented response (ie, CR) to PD or death.
Participants who did not experience PD or death were to be censored from the last tumor assessment.
Duration of response was to be estimated using Kaplan-Meier.
|
Up to approximately 1 year (at Baseline; every 6 weeks for the first 8 cycles, then every 12 weeks until progression or death; and up to 4 weeks after initial response)
|
Number of Participants Who Experienced PD or Death
Ramy czasowe: Up to approximately 1 year (at Baseline; every 6 weeks for the first 8 cycles, then every 12 weeks until progression or death; and up to 4 weeks after initial response)
|
Objective tumor response was assessed using RECIST.
PD was defined as the appearance of new lesion(s) or at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum obtained at Screening or during treatment.
Participants who withdrew from the study early for insufficient therapeutic response without tumor assessment for PD were also included within the definition of PD.
|
Up to approximately 1 year (at Baseline; every 6 weeks for the first 8 cycles, then every 12 weeks until progression or death; and up to 4 weeks after initial response)
|
Time to Progression
Ramy czasowe: Up to approximately 1 year (at Baseline; every 6 weeks for the first 8 cycles, then every 12 weeks until progression or death; and up to 4 weeks after initial response)
|
Objective tumor response was assessed using RECIST.
PD was defined as the appearance of new lesion(s) or at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum obtained at Screening or during treatment.
Participants who withdrew from the study early for insufficient therapeutic response without tumor assessment for PD were also included within the definition of PD.
Time to progression was defined as the time from treatment start to PD or death.
Participants who did not experience PD or death were censored from the last tumor assessment.
Time to progression was estimated using Kaplan-Meier and expressed in weeks.
|
Up to approximately 1 year (at Baseline; every 6 weeks for the first 8 cycles, then every 12 weeks until progression or death; and up to 4 weeks after initial response)
|
Number of Participants Who Experienced PD or Withdrew From the Study Early
Ramy czasowe: Up to approximately 1 year (at Baseline; every 6 weeks for the first 8 cycles, then every 12 weeks until progression or death; and up to 4 weeks after initial response)
|
Objective tumor response was assessed using RECIST.
PD was defined as the appearance of new lesion(s) or at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum obtained at Screening or during treatment.
|
Up to approximately 1 year (at Baseline; every 6 weeks for the first 8 cycles, then every 12 weeks until progression or death; and up to 4 weeks after initial response)
|
Time to Treatment Failure
Ramy czasowe: Up to approximately 1 year (at Baseline; every 6 weeks for the first 8 cycles, then every 12 weeks until progression or death; and up to 4 weeks after initial response)
|
Objective tumor response was assessed using RECIST.
PD was defined as the appearance of new lesion(s) or at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum obtained at Screening or during treatment.
Time to treatment failure was defined as the time from treatment start to PD or early withdrawal from the study for death, toxicity, refusal/noncompliance, insufficient therapeutic response, or failure to return.
Participants who did not experience PD or who did not withdraw from the study early were censored from the last tumor assessment.
Time to treatment failure was estimated using Kaplan-Meier and expressed in weeks.
|
Up to approximately 1 year (at Baseline; every 6 weeks for the first 8 cycles, then every 12 weeks until progression or death; and up to 4 weeks after initial response)
|
Percentage of Participants Who Died
Ramy czasowe: Up to approximately 2 years (from start of treatment until death)
|
The percentage of participants who died was calculated as [number of participants with event divided by the number analyzed] multiplied by 100.
|
Up to approximately 2 years (from start of treatment until death)
|
Overall Survival
Ramy czasowe: Up to approximately 2 years (from start of treatment until death)
|
Overall survival was defined as the time from treatment start to death.
Participants who did not die during follow-up were to be censored from the last known alive date.
Overall survival was to be estimated using Kaplan-Meier.
|
Up to approximately 2 years (from start of treatment until death)
|
Percentage of Participants Achieving a Best Overall Response of SD
Ramy czasowe: Up to approximately 1 year (at Baseline; every 6 weeks for the first 8 cycles, then every 12 weeks until progression or death; and up to 4 weeks after initial response)
|
Objective tumor response was assessed using RECIST.
SD was defined as neither sufficient shrinkage to quality for PR nor sufficient increase to qualify for PD.
The percentage of participants achieving a best overall response of SD was calculated as [number of participants meeting the above criteria divided by the number analyzed] multiplied by 100.
|
Up to approximately 1 year (at Baseline; every 6 weeks for the first 8 cycles, then every 12 weeks until progression or death; and up to 4 weeks after initial response)
|
Apparent Half-Life (t1/2) of Pertuzumab
Ramy czasowe: Pre-dose and within 15 minutes of the end of infusion on Day 1 of each cycle, and on Days 8 and 15 of Cycles 1 and 2
|
Serum samples were obtained for pharmacokinetic (PK) assessment using a receptor-binding, enzyme-linked immunosorbent assay (ELISA).
Pertuzumab concentrations at each collection point were used to determine the apparent t1/2 by non-compartmental analysis, defined as the time elapsed for pertuzumab concentrations to decrease by 50%.
The derived value was averaged among all participants and expressed in days.
|
Pre-dose and within 15 minutes of the end of infusion on Day 1 of each cycle, and on Days 8 and 15 of Cycles 1 and 2
|
Maximum Plasma Concentration (Cmax) of Pertuzumab
Ramy czasowe: Pre-dose and within 15 minutes of the end of infusion on Day 1 of each cycle, and on Days 8 and 15 of Cycles 1 and 2
|
Serum samples were obtained for PK assessment using a receptor-binding ELISA.
The maximum observed pertuzumab concentration across all collection points was documented.
Cmax was averaged among all participants and expressed in micrograms per milliliter (mcg/mL).
|
Pre-dose and within 15 minutes of the end of infusion on Day 1 of each cycle, and on Days 8 and 15 of Cycles 1 and 2
|
Time to Maximum Plasma Concentration (Tmax) of Pertuzumab
Ramy czasowe: Pre-dose and within 15 minutes of the end of infusion on Day 1 of each cycle, and on Days 8 and 15 of Cycles 1 and 2
|
Serum samples were obtained for PK assessment using a receptor-binding ELISA.
The time of maximum observed pertuzumab concentration across all collection points was documented.
Tmax was averaged among all participants and expressed in days.
|
Pre-dose and within 15 minutes of the end of infusion on Day 1 of each cycle, and on Days 8 and 15 of Cycles 1 and 2
|
Area Under the Concentration-Time Curve (AUC) of Pertuzumab
Ramy czasowe: Pre-dose and within 15 minutes of the end of infusion on Day 1 of each cycle, and on Days 8 and 15 of Cycles 1 and 2
|
Serum samples were obtained for PK assessment using a receptor-binding ELISA.
Pertuzumab concentrations at each collection point were used to determine AUC to the last measurable observation (AUClast) and AUC extrapolated to infinity (AUCinf) by non-compartmental analysis.
The derived values were averaged among all participants and expressed in days by micrograms per milliliter (days*mcg/mL).
|
Pre-dose and within 15 minutes of the end of infusion on Day 1 of each cycle, and on Days 8 and 15 of Cycles 1 and 2
|
Systemic Clearance (CL) of Pertuzumab
Ramy czasowe: Pre-dose and within 15 minutes of the end of infusion on Day 1 of each cycle, and on Days 8 and 15 of Cycles 1 and 2
|
Serum samples were obtained for PK assessment using a receptor-binding ELISA.
Pertuzumab concentrations at each collection point were used to determine CL by non-compartmental analysis, defined as the rate at which pertuzumab was removed from the body.
The derived value was averaged among all participants and expressed in milliliters per day (mL/day).
|
Pre-dose and within 15 minutes of the end of infusion on Day 1 of each cycle, and on Days 8 and 15 of Cycles 1 and 2
|
Volume of Distribution at Steady State (Vss) of Pertuzumab
Ramy czasowe: Pre-dose and within 15 minutes of the end of infusion on Day 1 of each cycle, and on Days 8 and 15 of Cycles 1 and 2
|
Serum samples were obtained for PK assessment using a receptor-binding ELISA.
Pertuzumab concentrations at each collection point were used to determine the Vss by non-compartmental analysis, defined as the theoretical volume at which the total amount of pertuzumab would be uniformly distributed to produce the desired concentration.
The derived value was averaged among all participants and expressed in milliliters (mL).
|
Pre-dose and within 15 minutes of the end of infusion on Day 1 of each cycle, and on Days 8 and 15 of Cycles 1 and 2
|
Mean Residence Time (MRT) of Pertuzumab
Ramy czasowe: Pre-dose and within 15 minutes of the end of infusion on Day 1 of each cycle, and on Days 8 and 15 of Cycles 1 and 2
|
Serum samples were obtained for PK assessment using a receptor-binding ELISA.
Pertuzumab concentrations at each collection point were used to determine the MRT by non-compartmental analysis.
The derived value was averaged among all participants and expressed in days.
|
Pre-dose and within 15 minutes of the end of infusion on Day 1 of each cycle, and on Days 8 and 15 of Cycles 1 and 2
|
Number of Participants Experiencing a Drop in Left Ventricular Ejection Fraction (LVEF) to a Value of Less Than 50%
Ramy czasowe: Up to approximately 1 year (at Baseline; at the end of Cycles 2, 4, 8, 12, and 16; and up to 7 weeks following the last infusion)
|
Echocardiography was performed to determine LVEF, defined as the volume of blood pumped from the left ventricle as a percentage of end-diastolic volume.
Theoretically, LVEF may range from 0 to 100%.
The number of participants experiencing a drop in LVEF greater than or equal to (≥) 10 or 15 percentage points to a final LVEF of less than (<) 50% is reported here.
|
Up to approximately 1 year (at Baseline; at the end of Cycles 2, 4, 8, 12, and 16; and up to 7 weeks following the last infusion)
|
Współpracownicy i badacze
Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.
Sponsor
Daty zapisu na studia
Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.
Główne daty studiów
Rozpoczęcie studiów
1 lutego 2003
Zakończenie podstawowe (Rzeczywisty)
1 kwietnia 2005
Ukończenie studiów (Rzeczywisty)
1 kwietnia 2005
Daty rejestracji na studia
Pierwszy przesłany
11 czerwca 2015
Pierwszy przesłany, który spełnia kryteria kontroli jakości
2 lipca 2015
Pierwszy wysłany (Oszacować)
8 lipca 2015
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Oszacować)
25 sierpnia 2015
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
24 sierpnia 2015
Ostatnia weryfikacja
1 sierpnia 2015
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- BO16934
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na Rak piersi
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)Aktywny, nie rekrutującyGruczolakorak gruczołu krokowego III stopnia AJCC v7 | Gruczolakorak gruczołu krokowego II stopnia AJCC v7 | Stopień I gruczolakoraka gruczołu krokowego American Joint Committee on Cancer (AJCC) v7Stany Zjednoczone
-
Emory UniversityNational Cancer Institute (NCI)WycofanePrognostyczny rak piersi IV stopnia AJCC v8 | Przerzutowy nowotwór złośliwy w mózgu | Przerzutowy rak piersi | Anatomiczny IV stopień raka piersi American Joint Committee on Cancer (AJCC) v8
-
Jonsson Comprehensive Cancer CenterZakończonyRak prostaty oporny na kastrację | Przerzutowy rak prostaty | Stadium IVA raka prostaty AJCC v8 | Rak prostaty w stadium IVB AJCC v8 | Rak prostaty w stadium IV American Joint Committee on Cancer (AJCC) v8Stany Zjednoczone
-
Jonsson Comprehensive Cancer CenterEli Lilly and Company; Genentech, Inc.RekrutacyjnyNiedrobnokomórkowy rak płuc z przerzutami | Oporny na leczenie niedrobnokomórkowy rak płuc | Rak płuca w stadium IV American Joint Committee on Cancer (AJCC) v8 | Rak płuc w stadium IVA AJCC v8 | Rak płuc w stadium IVB AJCC v8Stany Zjednoczone
-
Jonsson Comprehensive Cancer CenterZakończonyBiochemicznie nawracający rak prostaty | Przerzutowy rak prostaty | Nowotwór złośliwy z przerzutami w kości | Stadium IVA raka prostaty AJCC v8 | Rak prostaty w stadium IVB AJCC v8 | Rak prostaty w stadium IV American Joint Committee on Cancer (AJCC) v8Stany Zjednoczone
-
NRG OncologyNational Cancer Institute (NCI)Aktywny, nie rekrutującyAnatomiczny rak piersi IV stadium AJCC v8 | Prognostyczny rak piersi IV stopnia AJCC v8 | Nowotwór złośliwy z przerzutami w kości | Przerzutowy nowotwór złośliwy w węzłach chłonnych | Przerzutowy nowotwór złośliwy w wątrobie | Przerzutowy rak piersi | Przerzutowy nowotwór złośliwy w płucach | Nowotwór... i inne warunkiStany Zjednoczone, Kanada, Arabia Saudyjska, Republika Korei
-
Jonsson Comprehensive Cancer CenterRekrutacyjnyRak prostaty oporny na kastrację | Przerzutowy rak prostaty | Stadium IVA raka prostaty AJCC v8 | Rak prostaty w stadium IVB AJCC v8 | Rak prostaty w stadium IV American Joint Committee on Cancer (AJCC) v8Stany Zjednoczone
-
National Cancer Institute (NCI)ZakończonyOporny na leczenie złośliwy nowotwór lity | Nawracający złośliwy nowotwór lity | Przerzutowy złośliwy nowotwór lity | Nieoperacyjny lity nowotwór | Nawracający rak drobnokomórkowy płuca | Stopień IIIA Rak drobnokomórkowy płuca AJCC v7 | Etap IIIB Rak drobnokomórkowy płuca AJCC v7 | Rak drobnokomórkowy... i inne warunkiStany Zjednoczone
-
Jonsson Comprehensive Cancer CenterBeiGene; Driven To CureWycofanePrzerzutowy rak nerkowokomórkowy | Rak nerkowokomórkowy IV stopnia AJCC v8 | Rak brodawkowaty nerki | Zbieranie raka przewodów | Nieoperacyjny rak nerki | Dziedziczna leiomyomatoza i rak nerkowokomórkowy | Jasnokomórkowy brodawkowaty nowotwór nerki | Dziedziczny rak brodawkowaty nerki | Niesklasyfikowany... i inne warunkiStany Zjednoczone
-
Jonsson Comprehensive Cancer CenterAstraZenecaZakończonyRak płaskonabłonkowy jamy ustnej i gardła | Stopień kliniczny III zależny od HPV (p16-dodatni) rak jamy ustnej i gardła AJCC v8 | Stopień kliniczny II, w którym pośredniczy HPV (p16-dodatni) rak jamy ustnej i gardła AJCC v8 | Patologiczny etap I, w którym pośredniczy HPV (p16-dodatni) rak jamy... i inne warunkiStany Zjednoczone
Badania kliniczne na Pertuzumab
-
Shanghai Henlius BiotechZakończonyZdrowi ochotnicy płci męskiejChiny
-
Zydus Lifesciences LimitedJeszcze nie rekrutacja
-
European Organisation for Research and Treatment...Hoffmann-La RocheZakończonyPopulacja osób w podeszłym wieku z przerzutowym rakiem piersiBelgia, Włochy, Holandia, Francja, Polska, Zjednoczone Królestwo, Portugalia, Szwecja
-
Shengjing HospitalJeszcze nie rekrutacja
-
Genentech, Inc.Zakończony
-
Genentech, Inc.Zakończony
-
BiocadRekrutacyjny
-
Ontario Clinical Oncology Group (OCOG)Zakończony
-
BiocadAktywny, nie rekrutujący
-
National Institutes of Health Clinical Center (CC)National Cancer Institute (NCI)Zakończony